Ultra‐Fast Green UPLC‐MS/MS Method for the Quantification of Cediranib in the Human Liver Microsome Matrix: In Vitro and In Silico Metabolic Stability Assessment #ArchPharm onlinelibrary.wiley.com/doi/10.1002/...
Ultra‐Fast Green UPLC‐MS/MS Method for the Quantification of Cediranib in the Human Liver Microsome Matrix: In Vitro and In Silico Metabolic Stability Assessment
Cediranib is an oral pan-VEGF receptor tyrosine kinase inhibitor and a potent antiangiogenic agent. The in vitro t1/2 was determined to be 25.48 min, and the cediranib intrinsic clearance was determi...
onlinelibrary.wiley.com
September 27, 2025 at 6:44 PM
Ultra‐Fast Green UPLC‐MS/MS Method for the Quantification of Cediranib in the Human Liver Microsome Matrix: In Vitro and In Silico Metabolic Stability Assessment #ArchPharm onlinelibrary.wiley.com/doi/10.1002/...
A Tale of Two Cell Lines: Characterization of differential efficacy of small molecule drugs cediranib and NU-7441 on primary vs. metastatic colorectal cancer https://www.biorxiv.org/content/10.1101/2025.09.18.677116v1
September 21, 2025 at 3:49 PM
A Tale of Two Cell Lines: Characterization of differential efficacy of small molecule drugs cediranib and NU-7441 on primary vs. metastatic colorectal cancer https://www.biorxiv.org/content/10.1101/2025.09.18.677116v1
A Tale of Two Cell Lines: Characterization of differential efficacy of small molecule drugs cediranib and NU-7441 on primary vs. metastatic colorectal cancer https://www.biorxiv.org/content/10.1101/2025.09.18.677116v1
September 21, 2025 at 3:49 PM
A Tale of Two Cell Lines: Characterization of differential efficacy of small molecule drugs cediranib and NU-7441 on primary vs. metastatic colorectal cancer https://www.biorxiv.org/content/10.1101/2025.09.18.677116v1
Comparing #durvalumab, #olaparib, and #cediranib, or chemotherapy in platinum-resistant #ovariancancer: the @nrgonc.bsky.social GY023 trial
url:https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-24-3877/755490/Comparing-durvalumab-olaparib-and-cediranib
#gyncsm
url:https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-24-3877/755490/Comparing-durvalumab-olaparib-and-cediranib
#gyncsm
April 19, 2025 at 6:09 PM
Comparing #durvalumab, #olaparib, and #cediranib, or chemotherapy in platinum-resistant #ovariancancer: the @nrgonc.bsky.social GY023 trial
url:https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-24-3877/755490/Comparing-durvalumab-olaparib-and-cediranib
#gyncsm
url:https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-24-3877/755490/Comparing-durvalumab-olaparib-and-cediranib
#gyncsm
Cediranib and olaparib showed clinical activity in treating resistant ovarian cancer, but were not superior to standard chemotherapy.
by Lee JM, Brady MF (...) Secord AA et 21 al. in J Clin Oncol #MedSky
📖 read the article: https://ascopubs.org/doi/10.1200/JCO.24.00683
by Lee JM, Brady MF (...) Secord AA et 21 al. in J Clin Oncol #MedSky
📖 read the article: https://ascopubs.org/doi/10.1200/JCO.24.00683
December 29, 2024 at 12:47 PM
Cediranib and olaparib showed clinical activity in treating resistant ovarian cancer, but were not superior to standard chemotherapy.
by Lee JM, Brady MF (...) Secord AA et 21 al. in J Clin Oncol #MedSky
📖 read the article: https://ascopubs.org/doi/10.1200/JCO.24.00683
by Lee JM, Brady MF (...) Secord AA et 21 al. in J Clin Oncol #MedSky
📖 read the article: https://ascopubs.org/doi/10.1200/JCO.24.00683
📃Scientific paper: Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patien...
➡️ Continued on ES/IODE
➡️ Continued on ES/IODE
August 23, 2024 at 2:40 PM
📃Scientific paper: Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patien...
➡️ Continued on ES/IODE
➡️ Continued on ES/IODE